Polymer nanoparticles loaded with FeCl-tetraphenylporphyrin for binary catalytic therapy of neoplasms
- Authors: Faustova M.R.1, Nikolskaya E.D.1, Zhunina O.A.1, Mollaev M.D.1, Yabbarov N.G.1, Lobanov A.V.2,3, Melnikov M.Y.4, Severin E.S.1
-
Affiliations:
- OJSC Russian Research Center for Molecular Diagnostics and Therapy
- N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences
- G. V. Plekhanov Russian University of Economics
- Department of Chemistry, M. V. Lomonosov Moscow State University, Build. 3
- Issue: Vol 67, No 2 (2018)
- Pages: 359-365
- Section: Full Articles
- URL: https://journals.rcsi.science/1066-5285/article/view/242232
- DOI: https://doi.org/10.1007/s11172-018-2081-z
- ID: 242232
Cite item
Abstract
In order to study the possibility of using a metal complex of the porphyrin series, FeIIICl-tetraphenylporphyrin (FeClTPP), and its polymeric form as antitumor agents for binary catalytic therapy, the technology of preparation of polymer particles containing FeClTPP was developed for the first time. The experimental data obtained allow one to conclude that the developed form using a copolymer of lactic and glycolic acids (ratio of monomer units 50: 50), ultrasonic homogenization, D-mannitol (as a cryoprotectant), the active agent to polymer ratio 1: 10, and the organic to aqueous phase ratio 1: 10 and 1: 20, respectively, has the optimal physicochemical parameters. It was found that the free substance of FeClTPP and polymer particles with FeClTPP are active against MCF-7 (human breast adenocarcinoma), HeLa (human cervical carcinoma), and MG-63 (human osteosarcoma) cell lines. The polymer particles containing FeClTFP exhibit the highest cytotoxic effect against MCF-7 lines as compared to the free substance. The results of the study indicate that both the substance of tetraphenylporphyrin and its resulting polymeric form are promising for the treatment of tumor diseases in binary catalytic therapy.
About the authors
M. R. Faustova
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Russian Federation, 8 Simferopolsky bulv., Moscow, 117149
E. D. Nikolskaya
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Russian Federation, 8 Simferopolsky bulv., Moscow, 117149
O. A. Zhunina
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Russian Federation, 8 Simferopolsky bulv., Moscow, 117149
M. D. Mollaev
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Russian Federation, 8 Simferopolsky bulv., Moscow, 117149
N. G. Yabbarov
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Email: e.severin@mail.ru
Russian Federation, 8 Simferopolsky bulv., Moscow, 117149
A. V. Lobanov
N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences; G. V. Plekhanov Russian University of Economics
Email: e.severin@mail.ru
Russian Federation, 4 ul. Kosygina, Moscow, 119991; 36 Stremyannyi per., Moscow, 117997
M. Ya. Melnikov
Department of Chemistry, M. V. Lomonosov Moscow State University, Build. 3
Author for correspondence.
Email: melnikov46@mail.ru
Russian Federation, 1 Leninskiye Gory, Moscow, 119991
E. S. Severin
OJSC Russian Research Center for Molecular Diagnostics and Therapy
Author for correspondence.
Email: e.severin@mail.ru
Russian Federation, 8 Simferopolsky bulv., Moscow, 117149